Division of Thoracic Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
J Thorac Oncol. 2010 Oct;5(10):1594-601. doi: 10.1097/JTO.0b013e3181f1923b.
Women with non-small cell lung cancer (NSCLC) are more likely to have better survival than men. This study intended to assess gender differences in the survival of these patients in a large registry population.
In 2005, the Japanese Joint Committee for Lung Cancer Registration performed a nationwide retrospective registry study regarding the prognosis and clinicopathologic profiles of patients who underwent resection for primary lung neoplasms in 1999. The registry data of 12,509 patients with NSCLC were analyzed in terms of gender differences in prognosis and clinicopathologic features.
There were 8353 (66.8%) men and 4156 (33.2%) women with a mean age at operation of 66.4 and 65.0 years, respectively (p < 0.001). Women had a higher incidence of adenocarcinoma (p < 0.001) and stage IA disease (p < 0.001) than men. The overall survival was significantly better in women than men. The 5-year survival rates (5-YSRs) for women and men were 75.6 and 57.9%, respectively (p = 0.0000). According to histology, the overall survival of women was significantly better than that of men for both adenocarcinoma (5-YSR, 77.7 versus 61.9%, p = 0.0000) and nonadenocarcinoma (5-YSR, 59.3 versus 53.1%, p = 0.035). In adenocarcinoma, women had a significantly better prognosis than men for pathologic stage I/II disease. However, in nonadenocarcinoma, there was no significant prognostic difference between the two genders in pathologic stage I/II disease.
Women with NSCLC, especially with an adenocarcinoma histology, had better survival than men. Women were more likely to have adenocarcinoma and stage IA disease, which might account for the better prognosis in women.
与男性相比,患有非小细胞肺癌(NSCLC)的女性患者的生存情况更有可能更好。本研究旨在评估在大型登记人群中,这些患者的生存情况存在哪些性别差异。
2005 年,日本肺癌登记联合委员会针对 1999 年接受原发性肺肿瘤切除术的患者的预后和临床病理特征进行了一项全国性回顾性登记研究。对 12509 例 NSCLC 患者的登记数据进行了分析,以评估预后和临床病理特征方面的性别差异。
男性患者 8353 例(66.8%),女性患者 4156 例(33.2%),手术时的平均年龄分别为 66.4 岁和 65.0 岁(p<0.001)。女性患者的腺癌(p<0.001)和 IA 期疾病(p<0.001)的发生率更高。女性患者的总生存率明显高于男性患者。女性和男性患者的 5 年生存率(5-YSR)分别为 75.6%和 57.9%(p=0.0000)。根据组织学类型,女性腺癌(5-YSR 为 77.7%对 61.9%,p=0.0000)和非腺癌(5-YSR 为 59.3%对 53.1%,p=0.035)的总体生存率明显优于男性患者。在腺癌中,女性患者的病理分期 I/II 期疾病的预后明显优于男性患者。然而,在非腺癌中,两个性别在病理分期 I/II 期疾病方面没有显著的预后差异。
患有 NSCLC 的女性患者,特别是患有腺癌的女性患者,其生存情况明显好于男性患者。女性患者更有可能患有腺癌和 IA 期疾病,这可能是女性患者预后较好的原因。